28, February, 2024
HomeIndiaIndia's Bold Step: Launching HPV Vaccination Drive for Girls to Combat Cervical Cancer

India’s Bold Step: Launching HPV Vaccination Drive for Girls to Combat Cervical Cancer

Published on

In a significant move, the Indian government is gearing up to initiate a human papillomavirus (HPV) vaccination campaign targeting girls aged 9-14 years, with the aim of curbing cervical cancer rates, as reported by The Indian Express.

Read Also | Early Cancer Warning Signs and Tips for Prevention: Protecting Your Health

The three-phase immunization drive is set to kick off in the second quarter of this year, emphasizing the government’s commitment to addressing the pressing issue of cervical cancer, the second most common cancer among Indian women.

The cost-effective two-dose HPV vaccine, currently priced at approximately Rs. 2,000 per dose, is poised to become freely available as part of the government’s immunization program. This vaccine not only safeguards against cervical cancer but also offers protection against strains responsible for anal, vaginal, and oropharyngeal cancers, along with those causing genital warts.

The campaign will be strategically conducted in schools and existing vaccination sites, targeting a third of girls aged 9 to 14 years annually over the course of three years, as stated by a senior official. The launch is contingent upon the government accumulating 6.5-7 crore vaccine doses for the initial phase. Currently, India bears about one-fifth of the global burden of cervical cancer, with an alarming 1.25 lakh new cases and 75,000 deaths reported annually.

In parallel, the Serum Institute of India (SII) is proactively working to enhance its production capacity for Cervavac, a locally developed quadrivalent vaccine that protects against four HPV strains – 16, 18, 6, and 11. With an existing capacity of 2-3 million doses annually, SII aims to ramp up production to an impressive 60-70 million doses.

Additionally, there are explorations into a single-dose HPV vaccine for ages 9-15, advised by the National Immunization Technical Advisory Group (NITAG) to the Indian Council of Medical Research (ICMR).

Read Also | Indian Celebrities Who Triumphed Over Cancer: Inspirational Journeys

While the World Health Organization (WHO) suggests the viability of a single-dose schedule for public health programs, the ICMR plans to conduct an antibody persistence study post-one dose, steering away from a prolonged Phase-3 trial for efficacy. This innovative approach reflects India’s commitment to finding effective solutions in the battle against cervical cancer.

Latest articles

Exclusive Discounts – Maruti Unveils Massive Savings on MY2023 Vitara, Fronx Models

Maruti Suzuki dealerships are currently rolling out irresistible discounts, exceeding Rs. 1 lakh, on...

Mahindra Set to Unveil 5-Door Thar SUV with Enhanced Features in Q2 FY2025

Mahindra, a prominent player in the Indian automotive market, is set to introduce the...

Renault Scenic E-Tech EV Earns Coveted Car of the Year 2024 Award

Renault's Scenic E-Tech electric SUV has secured the prestigious title of Car of the...

More like this

IIT Madras Breakthrough: Indian Spice-Based Nanomedicine Revolutionizes Cancer Treatment

In a groundbreaking move, researchers at IIT Madras have patented a revolutionary cancer treatment...

Samajwadi Party’s Chief Whip Resigns Amid Rajya Sabha Polls in Uttar Pradesh

Samajwadi Party (SP) MLA and leader Manoj Kumar Pandey tendered his resignation as the...

Congress Pledges to Scrap Agnipath Scheme: Promises Reinstatement of Previous Recruitment System

In a significant announcement, the Congress party declared its commitment to abolishing the controversial...
Enable Notifications OK